Intermittent Fasting Cuts Liver Fat in Fatty Liver Disease, Meta-Analysis Finds
A meta-analysis of 8 studies finds intermittent fasting significantly reduces liver fat and improves key metabolic markers in MASLD patients.
Summary
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease, affects millions worldwide and currently has limited dietary treatment options. Researchers pooled data from eight clinical studies involving 389 patients to assess whether intermittent fasting could meaningfully reduce liver fat. The results were encouraging: intermittent fasting significantly lowered liver fat content and improved ultrasound-measured liver steatosis scores. It also reduced body weight, BMI, and triglyceride levels. These findings suggest intermittent fasting may be a practical, low-cost dietary strategy for slowing MASLD progression. However, the small number of included studies and modest total sample size mean larger, well-controlled trials are needed before firm clinical recommendations can be made.
Detailed Summary
Metabolic dysfunction-associated steatotic liver disease (MASLD) — recently renamed from non-alcoholic fatty liver disease (NAFLD) — is now one of the most prevalent liver conditions globally, driven by rising rates of obesity, insulin resistance, and metabolic syndrome. Despite its prevalence, lifestyle-based interventions remain incompletely defined, and whether intermittent fasting (IF) specifically targets liver fat accumulation has been an open question.
To address this, researchers at Southwest Medical University conducted a systematic review and meta-analysis, searching PubMed, Cochrane Library, Web of Science, and Embase for relevant studies. Eight clinical trials with a combined 389 participants met inclusion criteria. Statistical analyses were performed using Review Manager 5.3 and Stata 17.0, with results expressed as mean differences (MD) or standardized mean differences (SMD) with 95% confidence intervals.
The pooled results were statistically significant on multiple fronts. Intermittent fasting reduced liver fat content by a mean difference of 3.01 percentage points (95% CI: −5.84 to −0.18; P = 0.04) and improved the controlled attenuation parameter — a validated ultrasound marker of hepatic steatosis — by 18.64 dB/m (95% CI: −30.29 to −6.99; P = 0.002). Beyond the liver, IF also produced significant reductions in body weight, BMI, and triglycerides, reinforcing its systemic metabolic benefits.
These findings carry real clinical relevance. MASLD currently lacks FDA-approved pharmacological therapies for the majority of patients, making dietary interventions front-line management tools. IF's ability to reduce hepatic fat through caloric restriction and metabolic reprogramming — likely involving improved insulin sensitivity and enhanced fatty acid oxidation — makes it a compelling non-pharmacological option.
Important caveats temper enthusiasm. The meta-analysis included only eight studies with under 400 total participants, limiting statistical power. Heterogeneity in IF protocols (time-restricted eating vs. alternate-day fasting), patient populations, and follow-up durations also complicates generalizability. The authors appropriately call for multicenter randomized controlled trials before IF is formally adopted into MASLD clinical guidelines. Summary is based on the abstract only.
Key Findings
- Intermittent fasting reduced liver fat content by ~3% in MASLD patients (P = 0.04).
- IF improved controlled attenuation parameter (CAP) by 18.64 dB/m, a validated liver steatosis marker (P = 0.002).
- IF significantly reduced body weight, BMI, and triglycerides in MASLD patients.
- Meta-analysis pooled 8 studies and 389 participants across multiple databases.
- Authors call for multicenter RCTs to confirm findings and guide clinical practice.
Methodology
This was a systematic review and meta-analysis searching PubMed, Cochrane Library, Web of Science, and Embase. Eight studies totaling 389 participants were included, with results analyzed using Review Manager 5.3 and Stata 17.0. Outcomes were reported as mean differences or standardized mean differences with 95% confidence intervals.
Study Limitations
The meta-analysis included only eight studies with 389 total participants, limiting statistical power and generalizability. Heterogeneity in IF protocols, patient populations, disease severity, and follow-up durations may affect the reliability of pooled estimates. Additionally, this summary is based on the abstract only, as the full text was not available for review.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: